Cas:13074-65-2 2-Hexylcyclopentan-1-one manufacturer & supplier

Chemical Name:2-Hexylcyclopentan-1-one

CAS.NO:13074-65-2

Synonyms:L5VTJ B6;2-N-HEXYLCYCLOPENTANONE;2-Hexylcyclopentanone;2-Hexylcyclopentan-1-one;2041950;Cyclopentanone, 2-hexyl-;EINECS 235-970-6;MFCD00059516

Molecular Formula:C₁₁H₂₀O

Molecular Weight:168.276

HS Code:2914299000

Physical and Chemical Properties:

Melting point:N/A

Boiling point:234.9±8.0 °C at 760 mmHg

Density:0.9±0.1 g/cm3

Index of Refraction:1.453

PSA:17.07000

Exact Mass:168.151413

LogP:3.35

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like L5VTJ B6 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00059516 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2041950 Use and application,EINECS 235-970-6 technical grade,usp/ep/jp grade.

Related News: He said it is “normal” for scientists and clinicians to discuss and debate data from experiments and clinical trials, but added those discussions have taken a turn “outside the boundaries of legitimate scientific deliberation.” Oxidase, cytochrome (Tomicus piniperda strain P-JL1 host Pinussylvestris/Pinus tabulaeformis country China mitochondria-encodedgene COI subunit I C-terminal fragment) manufacturers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. Virkon suppliers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. icofungipen vendor & factory “This announcement reflects another important regulatory milestone in the development of this medicine,” said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.,He said it is “normal” for scientists and clinicians to discuss and debate data from experiments and clinical trials, but added those discussions have taken a turn “outside the boundaries of legitimate scientific deliberation.”